## Carrie L Langstraat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2089352/publications.pdf

Version: 2024-02-01

516710 434195 1,043 39 16 31 citations g-index h-index papers 39 39 39 1379 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecologic Oncology, 2016, 142, 311-316.	1.4	103
2	Using Bundled Interventions to Reduce Surgical Site Infection After Major Gynecologic Cancer Surgery. Obstetrics and Gynecology, 2016, 127, 1135-1144.	2.4	95
3	Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer. Gynecologic Oncology, 2017, 147, 104-109.	1.4	92
4	Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecologic Oncology, 2016, 140, 15-21.	1.4	80
5	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	4.7	67
6	Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. Journal of Clinical Oncology, 2021, 39, 2594-2604.	1.6	66
7	Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecologic Oncology, 2017, 145, 21-26.	1.4	58
8	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 475-483.	4.7	45
9	Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gynecologic Oncology, 2017, 144, 266-273.	1.4	38
10	Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer. Gynecologic Oncology, 2019, 155, 58-62.	1.4	31
11	Enhanced Recovery after Minimally Invasive Gynecologic Procedures with Bowel Surgery: A Systematic Review. Journal of Minimally Invasive Gynecology, 2019, 26, 288-298.	0.6	28
12	Implementing robotic surgery for uterine cancer in the United States: Better outcomes without increased costs. Gynecologic Oncology, 2020, 156, 451-458.	1.4	27
13	Management and outcomes of primary vaginal Cancer. Gynecologic Oncology, 2020, 159, 456-463.	1.4	27
14	Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer. Gynecologic Oncology, 2019, 152, 286-292.	1.4	26
15	A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab. Gynecologic Oncology Reports, 2020, 32, 100574.	0.6	26
16	Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management. Gynecologic Oncology, 2020, 157, 572-577.	1.4	19
17	Frozen Section for Detection of Lymph Nodes After Cervical Injection with Indocyanine Green (ICG) for Sentinel Lymph Node Technique in Endometrial Cancer Staging. Annals of Surgical Oncology, 2018, 25, 3692-3698.	1.5	17
18	Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecologic Oncology, 2019, 152, 223-227.	1.4	17

#	Article	IF	CITATIONS
19	Role of delayed interval debulking for persistent residual disease after more than 5Âcycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecologic Oncology, 2020, 159, 434-441.	1.4	16
20	Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. Gynecologic Oncology, 2020, 158, 646-652.	1.4	16
21	Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia < sup />. Journal of Women's Health, 2017, 26, 368-373.	3.3	15
22	Comparing survival outcomes between surgical and radiographic lymph node assessment in locally advanced cervical cancer: A propensity score-matched analysis. Gynecologic Oncology, 2020, 156, 320-327.	1.4	15
23	Survival outcomes in patients with cervical cancer treated with open versus robotic radical hysterectomy: Our surgical pathology interrogation. Gynecologic Oncology, 2020, 159, 373-380.	1.4	15
24	Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy. Gynecologic Oncology, 2021, 160, 681-687.	1.4	13
25	Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy. Gynecologic Oncology, 2018, 149, 291-296.	1.4	12
26	External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis. International Journal of Gynecological Cancer, 2020, 30, 797-805.	2.5	11
27	The shift from inpatient to outpatient hysterectomy for endometrial cancer in the United States: trends, enabling factors, cost, and safety. International Journal of Gynecological Cancer, 2021, 31, 686-693.	2.5	9
28	Advanced ovarian cancer patients identify opportunities for prehabilitation: A qualitative study. Gynecologic Oncology Reports, 2021, 36, 100731.	0.6	9
29	Overall survival after surgical staging by lymph node dissection versus sentinel lymph node biopsy in endometrial cancer: a national cancer database study. International Journal of Gynecological Cancer, 2022, 32, 28-40.	2.5	7
30	Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses. Gynecologic Oncology, 2017, 147, 514-520.	1.4	6
31	Impact of Sentinel Node Approach in Gynecologic Cancer on Training Needs. Journal of Minimally Invasive Gynecology, 2019, 26, 727-732.	0.6	6
32	Sequencing chemotherapy before radiotherapy for women with stage IIIC endometrial cancer. International Journal of Gynecological Cancer, 2021, 31, 702-708.	2.5	6
33	Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature. Gynecologic Oncology Reports, 2022, 39, 100923.	0.6	6
34	Provider Knowledge and Support of Uterus Transplantation: Surveying Multidisciplinary Team Members. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 150-158.	2.4	5
35	Image-guided tumor ablation in gynecologic oncology: Review of interventional oncology techniques and case examples highlighting a collaborative, multidisciplinary program. Gynecologic Oncology, 2021, 160, 835-843.	1.4	5
36	Using quality improvement to increase the awareness of obesity among endometrial cancer patients. International Journal of Gynecological Cancer, 2019, 29, 1010-1015.	2.5	5

#	Article	IF	CITATIONS
37	Paraneoplastic nodular regenerative hyperplasia of the liver associated with placental site trophoblastic tumor. Gynecologic Oncology Reports, 2019, 29, 16-19.	0.6	3
38	Surgical Science–Simbionix Robotic Hysterectomy Simulator: Validating a New Tool. Journal of Minimally Invasive Gynecology, 2022, 29, 759-766.	0.6	1
39	Review of the Outcomes of Ovarian Cancer Treated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy. Indian Journal of Gynecologic Oncology, 2019, 17, 1.	0.3	o